The Rationale and Future Potential of Angiogenesis Inhibitors in Neoplasia
- 1 January 1999
- journal article
- review article
- Published by Springer Nature in Drugs
- Vol. 58 (1) , 17-38
- https://doi.org/10.2165/00003495-199958010-00003
Abstract
Malignant tumours are angiogenesis-dependent diseases. Several experimental studies suggest that primary tumour growth, invasiveness and metastasis require neovascularisation. Tumour-associated...Keywords
This publication has 98 references indexed in Scilit:
- Patterns and Emerging Mechanisms of the Angiogenic Switch during TumorigenesisPublished by Elsevier ,1996
- Inhibition of Angiogenesis by Thrombospondin-2Biochemical and Biophysical Research Communications, 1995
- Expression of Vascular Endothelial Growt Factor and Its Receptors fit and KDR in Ovarian CarcinomaJNCI Journal of the National Cancer Institute, 1995
- Dormancy of micrometastases: Balanced proliferation and apoptosis in the presence of angiogenesis suppressionNature Medicine, 1995
- Does improved control of tumour growth require an anti-cancer therapy targeting both neoplastic and intratumoral endothelial cells?European Journal Of Cancer, 1994
- Thalidomide is an inhibitor of angiogenesis.Proceedings of the National Academy of Sciences, 1994
- Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivoNature, 1993
- What Is the Evidence That Tumors Are Angiogenesis Dependent?JNCI Journal of the National Cancer Institute, 1990
- Induction of angiogenesis during the transition from hyperplasia to neoplasiaNature, 1989
- Tumor Angiogenesis: Therapeutic ImplicationsNew England Journal of Medicine, 1971